Impact of Anti-nuclear Antibody Seropositivity on Clinicopathological Parameters, Treatment Response, and Survival in Lymphoma Patients.
Mahendra KumarGaurav PrakashAmanjit BalAnu KumariYashwant KumarRanjeet BhardwajPankaj MalhotraRanjana W MinzPublished in: Asian Pacific journal of cancer prevention : APJCP (2024)
ANA is more frequent in lymphoma and increases further after chemotherapy. Higher mean age, early stage, and infrequent B symptoms were found to be significantly more frequent in ANA-positive lymphoma patients; however, only limited evidence supports its role as a prognostic marker or response to therapy. A wider study with appropriate follow-up data and molecular assay could shed light on the immunobiology of ANA production and its more defined clinical utility in lymphoma.
Keyphrases
- end stage renal disease
- early stage
- diffuse large b cell lymphoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- stem cells
- squamous cell carcinoma
- high throughput
- lymph node
- mesenchymal stem cells
- depressive symptoms
- bone marrow
- machine learning
- single molecule
- patient reported
- neoadjuvant chemotherapy